LncRNA ZFAS1 confers inflammatory responses and reduces cholesterol efflux in atherosclerosis through regulating miR-654-3p-ADAM10/RAB22A axis

Tang, Xiaoqiang; Yin, Ruohan; Shi, Haifeng; Wang, Xiang; Shen, Dong; Wang, Xiaoqin; Pan, Changjie

doi:10.1016/j.ijcard.2020.03.056

Cited by 48 publications

(29 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, the oncogenic LncRNA zinc finger NFX1-type containing one antisense RNA 1 (ZFAS1) is a viable target to ameliorate the development of AS because it reduces the cholesterol efflux rate and facilitates inflammation (Tang et al, 2020). In THP-1 macrophage-induced macrophages, overexpressing ZFAS1 promotes inflammatory responses and blocks cholesterol efflux.…”

Section: Long Noncoding Rnas In Macrophage Cholesterol Metabolismmentioning

confidence: 99%

“…ZFAS1 is an upstream factor for miR-654-3p, which can target and suppress the expression of ADAM10 and RAB22A. In short, ZFAS1 can positively mediate the expression of ADAM10 and RAB22A by sponging miR-654-3p (Tang et al, 2020).…”

Section: Long Noncoding Rnas In Macrophage Cholesterol Metabolismmentioning

confidence: 99%

“…LncRNAs can be upstream targets of miRNAs. For example, the macrophage anti-atherosclerotic lncRNA ZFAS1 serves as sponge that binds to miR-654-3p and improves the expression of ADAM10 and RAB22A (Tang et al, 2020). Moreover, some lncRNAs "sponges" are capable of interacting with more than one miRNA.…”

Section: Long Noncoding Rnas As Potential Biomarkers and Therapeutic mentioning

confidence: 99%

See 2 more Smart Citations

Functioning of Long Noncoding RNAs Expressed in Macrophage in the Development of Atherosclerosis

Liu

Chen

2020

Front. Pharmacol.

View full text Add to dashboard Cite

Chronic inflammation is part of the pathological process during atherosclerosis (AS). Due to the abundance of monocytes/macrophages within the arterial plaque, monocytes/macrophages have become a critical cellular target in AS studies. In recent decades, a number of long noncoding RNAs (lncRNAs) have been found to exert regulatory roles on the macrophage metabolism and macrophage plasticity, consequently promoting or suppressing atherosclerotic inflammation. In this review, we provide a comprehensive overview of lncRNAs in macrophage biology, highlighting the potential role of lncRNAs in AS based on recent findings, with the aim to identify disease biomarkers and future therapeutic interventions for AS.

show abstract

Section: Long Noncoding Rnas In Macrophage Cholesterol Metabolismmentioning

confidence: 99%

Section: Long Noncoding Rnas In Macrophage Cholesterol Metabolismmentioning

confidence: 99%

Section: Long Noncoding Rnas As Potential Biomarkers and Therapeutic mentioning

confidence: 99%

See 1 more Smart Citation

Functioning of Long Noncoding RNAs Expressed in Macrophage in the Development of Atherosclerosis

Liu

Chen

2020

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Similarly, Tang et al also reported that lncRNA ZFAS1 was upregulated in an in vitro model of atherosclerosis (THP-1 macrophage-derived foam cells). Overexpression of ZFAS1 promoted inflammatory responses and decreased cholesterol efflux by upregulating ADAM10/RAB22A expression [ 55 ].…”

Section: Regulation Of Lncrna and Determinants Of Statin Efficacymentioning

confidence: 99%

Regulation of Long Non-Coding RNAs by Statins in Atherosclerosis

et al. 2021

View full text Add to dashboard Cite

Despite increased public health awareness, atherosclerosis remains a leading cause of mortality worldwide. Significant variations in response to statin treatment have been noted among different populations suggesting that the efficacy of statins may be altered by both genetic and environmental factors. The existing literature suggests that certain long noncoding RNAs (lncRNAs) might be up- or downregulated among patients with atherosclerosis. LncRNA may act on multiple levels (cholesterol homeostasis, vascular inflammation, and plaque destabilization) and exert atheroprotective or atherogenic effects. To date, only a few studies have investigated the interplay between statins and lncRNAs known to be implicated in atherosclerosis. The current review characterizes the role of lncRNAs in atherosclerosis and summarizes the available evidence related to the effect of statins in regulating lncRNAs.

show abstract

“…ZFAS1 serves a role in atherosclerosis (15) and a variety of cancer types (16)(17)(18)(19), such as ovarian cancer, breast cancer, prostate cancer and hepatocellular carcinoma. ZFAS1 is a candidate biomarker predictive of the prognosis of thyroid carcinoma (20).…”

Section: Introductionmentioning

confidence: 99%

Downregulation of lncRNA ZFAS1 inhibits the hallmarks of thyroid carcinoma via the regulation of miR‑302‑3p on cyclin D1

et al. 2020

View full text Add to dashboard Cite

At present, treatment options for thyroid carcinoma remain limited. The present study aimed to investigate the role of ZFAS1 in various major hallmarks of cancer and the underlying mechanisms in thyroid carcinoma cells. The interactions between long non-coding RNAs (lncRNAs), microRNAs (miRs) and target genes were predicted by bioinformatics and confirmed by performing dual-luciferase assays. The mRNA and protein expressions were determined by reverse transcription-quantitative PCR and western blotting. Cell invasion, migration, and viability were evaluated via Transwell, wound-healing and Cell Counting Kit-8 assays, respectively. The results demonstrated that lncRNA ZFAS1 expression was upregulated in thyroid carcinoma tissues, TT and SW579 cells, and was associated with the proliferation of these two cell lines. Notably, downregulation ZFAS1 reduced migration and invasion, and reversed the promotive effects of miR-302a-3p inhibitor on the proliferation, migration and invasion of TT and SW579 cells. Moreover, cyclin D1 (CCND1) is targeted by miR-302a-3p, and was regulated by ZFAS1. In addition, the downregulation of ZFAS1 not only reversed the promotive effects of miR-302a-3p inhibitor on CCND1 expression and the epithelial-mesenchymal transition (EMT) of TT and SW579 cells, but also targeted and increased the expression of miR-302a-3p, and further reduced the expression of CCND1, resulting in suppression of the proliferation, migration, invasion and EMT of thyroid carcinoma cells.

show abstract

LncRNA ZFAS1 confers inflammatory responses and reduces cholesterol efflux in atherosclerosis through regulating miR-654-3p-ADAM10/RAB22A axis

Cited by 48 publications

References 31 publications

Functioning of Long Noncoding RNAs Expressed in Macrophage in the Development of Atherosclerosis

Functioning of Long Noncoding RNAs Expressed in Macrophage in the Development of Atherosclerosis

Regulation of Long Non-Coding RNAs by Statins in Atherosclerosis

Downregulation of lncRNA ZFAS1 inhibits the hallmarks of thyroid carcinoma via the regulation of miR‑302‑3p on cyclin D1

Contact Info

Product

Resources

About

LncRNA ZFAS1 confers inflammatory responses and reduces cholesterol efflux in atherosclerosis through regulating miR-654-3p-ADAM10/RAB22A axis

Cited by 48 publications

References 31 publications

Functioning of Long Noncoding RNAs Expressed in Macrophage in the Development of Atherosclerosis

Functioning of Long Noncoding RNAs Expressed in Macrophage in the Development of Atherosclerosis

Regulation of Long Non-Coding RNAs by Statins in Atherosclerosis

Downregulation of lncRNA ZFAS1 inhibits the hallmarks of thyroid carcinoma via the regulation of miR‑302‑3p on cyclin&nbsp;D1

Contact Info

Product

Resources

About

Downregulation of lncRNA ZFAS1 inhibits the hallmarks of thyroid carcinoma via the regulation of miR‑302‑3p on cyclin D1